

Genprex, Inc.

10:51 11 Sep 2019

Genprex's active drug ingredient shown to prevent tumors, according to medical journal

Genprex (NASDAQ:GNPX) has said the active ingredient in immunogene therapy Oncoprex has been shown to prevent tumor growth in triple-negative breast cancer (TNBC) by independent researcher.

In a statement on Wednesday, the company noted that a study published in the medical Journal "Nature", researchers found that TUSC2, the lead component of the drug, acts as a tumor-preventing gene.

The study discovered that MicroRNA-138, a biomarker associated with the particularly aggressive form of breast cancer, targets TUSC2 and restricts it. However, increasing the production of TUSC2 reduces miRNA-138 and frees up TUSC2 to suppress tumors.

Investors took the news and ran with it, bumping Genprex stock nearly 15% higher to \$0.99 Wednesday morning.

READ: Genprex unveils anticipated milestones, future guidance on the clinical development programs for its Oncoprex immunogene therapy

"The results of the study evaluating TUSC2 for the treatment of triple-negative breast cancer are encouraging," CEO Rodney Varner said in a statement. "We believe that the data reported in this Nature article by independent researchers supports our belief that TUSC2 may be effective to treat a variety of cancers, including some of the most deadly types of cancer."

That's where Oncoprex, which contains TUSC2, could come in.

The company is currently undergoing clinical and pre-clinical research about the effectiveness of TUSC2 when combined with other therapies and immunotherapies in small-cell lung cancer.

Other data, the company said, indicated TUSC2 may also be effective at combating glioblastoma, head and neck cancer, kidney cancer, and soft tissue sarcomas.

The study was published under the title, "MicroRNA-138 is a Prognostic Biomarker for Triple-Negative Breast Cancer and Promotes Tumorigenesis via TUSC2 repression".

—Updated to include stock movement—

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Price: 0.2891

Market Cap: \$5.5 m

1 Year Share Price Graph



December 2018 June 2019 December 20

Share Information

Code: GNPX

Listing: NASDAQ

52 week	High	Low
	2.25	0.2449

Sector: Pharma & Biotech

Website: www.genprex.com

Company Synopsis:

Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex's initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).